Leucine/sildenafil/metformin companion diagnostic - NuSirt Biopharma/OWL Metabolomics

Drug Profile

Leucine/sildenafil/metformin companion diagnostic - NuSirt Biopharma/OWL Metabolomics

Latest Information Update: 23 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NuSirt Biopharma
  • Developer NuSirt Biopharma; One Way Liver Genomics
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Non-alcoholic fatty liver disease

Most Recent Events

  • 23 Sep 2016 Investigation in Non-alcoholic fatty liver disease (Diagnosis) in USA (unspecified route)
  • 20 Sep 2016 NuSirt Biopharma and One way liver metabolomics collaborates to develop diagnostic tools for drug, NS 0200
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top